Fibromyalgia: Symptoms and Causes

Abdul Ali Abdellatif, M.D., underscores the importance of understanding all treatment options for gout, particularly for transplant patients, including the effectiveness of infusion therapy for those who do not respond to standard medications.

Megan Clowse discusses the promising results of the PHOENYCS GO study, which showed that the drug dapirolizumab pegol (DZP) significantly reduced lupus disease activity over 48 weeks.

Mona Amin, DO, explains why consistent gout treatment is essential to preventing joint damage, flares and long-term complications.

With the right treatment plan, patients with gout can prevent painful attacks and long-term complications.

Many patients initially believe gout is only about diet, but Jigar Shah, M.D., breaks down why medical management is essential.

Gout and chronic kidney disease (CKD) are closely linked, requiring careful management to prevent worsening kidney function and joint complications.

Inozyme Pharma’s ongoing clinical trials show encouraging signs that its investigational treatment could prevent or reverse rickets in children with rare genetic disorders.

Think you know the facts about RA? Take this quiz to find out!

Brittany Panico, DO, explains why uncontrolled gout isn’t just about diet — it’s a genetic and systemic disorder that requires proper medical management.

A genetic analysis revealed a link between insomnia and an 11% increased risk of RA, suggesting a biological connection beyond stress and inflammation.

Stacey Kennedy-Conner shares her inspiring journey of becoming a patient advocate and educator with the PALS program, promoting diversity and participation in lupus research.

Natasha Trehan’s foundation began as a platform for connection and now delivers scholarships, workshops and tailored programs to support young patients managing rheumatic diseases.

Stacie Bell, Ph.D., highlights the PALS program, which provides peer-to-peer education and support to strengthen patients’ confidence in navigating clinical trials.

Ejim Mark, M.D., M.P.H., discusses promising new data on zasocitinib, a next-generation TYK2 inhibitor, highlighting its potential to effectively and safely manage psoriatic arthritis.

Abdul Ali Abdellatif, M.D., underscores the importance of understanding all treatment options for gout, particularly for transplant patients, including the effectiveness of infusion therapy for those who do not respond to standard medications.

Megan Clowse discusses the promising results of the PHOENYCS GO study, which showed that the drug dapirolizumab pegol (DZP) significantly reduced lupus disease activity over 48 weeks.